Search

Displaying results 601 - 610 of 10000 in total
  1. Drug

    Pravastatin

    go.drugbank.com/drugs/DB00175
    ApprovedInvestigational

    [T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. … [L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained.

    Products: PRAVASTATINA EG
  2. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

  3. Drug

    Ferrous cation

    go.drugbank.com/drugs/DB14510
    Investigational

    Synonyms: Ferrous ion, Iron(2+) ionProducts: FERRO GLUCONATO EG, RULOFER N
  4. Drug

    Pixantrone

    go.drugbank.com/drugs/DB06193
    ApprovedWithdrawn

    Pixantrone was designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma(NHL) in patients who have failed two prior lines of therapy. [2] For patients suffering from NHL, first line therapies … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.

  5. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    [A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalProducts: CELECOXIB EG
  6. Drug

    Donepezil

    go.drugbank.com/drugs/DB00843
    ApprovedInvestigational

    [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. … Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.

    Products: DONEPEZIL EG
  7. Drug

    Gentamicin

    go.drugbank.com/drugs/DB00798
    ApprovedInvestigationalVet approved

    Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. … [A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity

    Mixtures: GENTAMICINA E BETAMETASONE EG, GENTAMICINA E BETAMETASONE IDIProducts: REFOBACIN BONE CEMENT R, GENTAMICINA EG
  8. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma

  9. Drug

    Ramipril

    go.drugbank.com/drugs/DB00178
    ApprovedInvestigational

    It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. … Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular

    Mixtures: RAMIPRIL E AMLODIPINA EG, RAMIPRIL E AMLODIPINA EGCategories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    progression on at least one line of endocrine therapy. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with